NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Haifeng Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project, Scientific Innovation Project of Shanghai Education Committee.
Abstract (Originalsprache)
N‐myc and STAT interactor (NMI) has been reported to interact with several transcription factors, including STATs family, c‐Myc, N‐Myc, and BRCA1, to indirectly affect transcription events and participate in multiple cellular processes. However, its function in pancreatic ductal adenocarcinoma (PDAC) has seldom been studied. In this study, we investigated the regulation of NMI on PDAC progression and uncovered the underlying molecular mechanisms. We found that NMI expression was significantly upregulated in PDAC and high NMI expression was related to a worse patient survival. Cell proliferation and migration assay, including cell viability, transwell assay, wound healing, and subcutaneous mouse model were utilized to confirm the function of NMI in PDAC progression. Downregulation of NMI abrogates tumor progression of PDAC both in vitro and in vivo. RNA sequencing was utilized to identify the downstream molecules of NMI and interferon‐induced protein with tetratricopeptide repeats 3 (IFIT3) was confirmed to be regulated by NMI in both mRNA and protein level. The binding function of NMI to STAT3 was essential in regulating the IFIT3 expression. Moreover, the NMI/STAT3‐IFIT3 axis was identified to markedly facilitate the gemcitabine resistance in PDAC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Shanghai Pancreatic Cancer Institute, Shanghai, China.
- Pancreatic Cancer Institute, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project
- Scientific Innovation Project of Shanghai Education Committee
- Clinical Research Plan of Shanghai Hospital Development Center
- Xuhui District Artificial Intelligence Medical Hospital Cooperation Project
- Science and Technology Commission of Shanghai Municipality
- National Science Foundation of China
Zitieren
APA
Hu, H., Li, B., Chen, H., Fan, G., Ye, Z., Ji, S., Yu, X., Xu, X., & Qin, Y. (2024). NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23645
Vancouver
Hu H, Li B, Chen H, Fan G, Ye Z, Ji S, et al. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23645
BibTeX
@article{Hu2024,
author = {Hu, Haifeng and Li, Borui and Chen, Haidi and Fan, Guixiogn and Ye, Zeng and Ji, Shunrong and Yu, Xianjun and Xu, Xiaowu and Qin, Yi},
title = {NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3‐IFIT3 axis},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23645}
}
EUVIMED